SAN FRANCISCO - June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that clinical and preclinical data from its oral GLP-1 receptor agonist GSBR-1290 program will be presented at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions taking place June 23-26, 2023, in San Diego, CA.
“The internal discovery of GSBR-1290 speaks to our expertise and long-term commitment to leveraging our structure-based drug discovery platform to design innovative small molecule therapies against the incretin and gut hormone family of G-protein coupled receptors,” said Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics. “Advancing GSBR-1290 into a first-in-human Phase 1 study marked a significant milestone for Structure Therapeutics. This molecule demonstrated encouraging safety and tolerability and we are looking forward to further studying its efficacy and safety profile in type 2 diabetes and obesity patients in the recently initiated Phase 2a study.”
Clinical and pre-clinical presentations include:
Poster presentation (#754): A First-in-Human Single Ascending Dose Study of GSBR-1290, a Novel Small Molecule GLP-1 Receptor Agonist, in Healthy Volunteers
- Date: Sunday, June 25, 2023
- Presentation Time: 11:30 a.m. – 12:30 p.m. PT
- Session: Clinical Therapeutics—Incretin-Based Therapies
Poster presentation (#760): Discovery of GSBR-1290, a highly potent, orally available, novel small molecule GLP-1 receptor agonist
- Date: Sunday, June 25, 2023
- Presentation Time: 11:30 a.m. – 12:30 p.m. PT
- Session: Clinical Therapeutics—Incretin-Based Therapies
A copy of the presentation materials can be accessed by visiting the “Pipeline” section of the Structure Therapeutics website after the conclusion of the presentations and will be archived on the Structure Therapeutics website.
About GSBR-1290
GSBR-1290 is an orally-available, small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of type 2 diabetes (T2DM) and obesity. The Company completed its Phase 1 single ascending dose (SAD) study in September 2022. GSBR-1290 was generally well tolerated and demonstrated dose-dependent pharmacokinetic (PK) and pharmacodynamic (PD) activity in 48 healthy volunteers.
The Company has completed dosing of its Phase 1b multiple ascending dose (MAD) study focused on safety, PK and tolerability in 24 healthy volunteers, and has initiated a Phase 2a study in T2DM and obesity. Topline data from the Phase 1b MAD study and the Phase 2a study are expected to be announced in the latter half of the fourth quarter of 2023.
About Structure Therapeutics
Structure Therapeutics is a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative oral treatments for chronic metabolic and pulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the company has established a scientifically-driven, GPCR-targeted pipeline, featuring two wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.